| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 54.78% | Cantor Fitzgerald | → $14 | Reiterates | Overweight → Overweight |
| 08/03/2023 | 32.67% | Oppenheimer | → $12 | Reiterates | Perform → Perform |
| 08/03/2023 | 110.06% | Chardan Capital | $22 → $19 | Maintains | Buy |
| 06/13/2023 | 65.84% | Cantor Fitzgerald | → $15 | Reiterates | Overweight → Overweight |
| 06/13/2023 | 87.95% | Raymond James | → $17 | Upgrades | Market Perform → Outperform |
| 05/09/2023 | 32.67% | Oppenheimer | → $12 | Reiterates | → Perform |
| 05/08/2023 | -11.55% | RBC Capital | $7 → $8 | Maintains | Sector Perform |
| 05/08/2023 | 54.78% | Credit Suisse | $15 → $14 | Maintains | Neutral |
| 05/08/2023 | 143.23% | Chardan Capital | → $22 | Reiterates | → Buy |
| 02/23/2023 | 65.84% | Credit Suisse | $13 → $15 | Maintains | Neutral |
| 02/23/2023 | 143.23% | Chardan Capital | $35 → $22 | Maintains | Buy |
| 02/23/2023 | 10.56% | RBC Capital | $14 → $10 | Maintains | Sector Perform |
| 02/01/2023 | 65.84% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 01/24/2023 | -22.61% | Morgan Stanley | $8 → $7 | Maintains | Underweight |
| 01/23/2023 | -22.61% | SVB Leerink | $6 → $7 | Maintains | Market Perform |
| 01/10/2023 | -33.67% | SVB Leerink | $7 → $6 | Maintains | Market Perform |
| 01/04/2023 | 298.01% | Wells Fargo | $50 → $36 | Maintains | Overweight |
| 12/13/2022 | 21.61% | Citigroup | → $11 | Initiates Coverage On | → Neutral |
| 12/06/2022 | 43.73% | Credit Suisse | → $13 | Assumes | → Neutral |
| 11/18/2022 | 65.84% | B of A Securities | $18 → $15 | Maintains | Neutral |
| 11/18/2022 | 286.95% | Truist Securities | $80 → $35 | Maintains | Buy |
| 11/18/2022 | 99% | Baird | $25 → $18 | Maintains | Outperform |
| 11/18/2022 | -11.55% | Morgan Stanley | $10 → $8 | Maintains | Underweight |
| 11/18/2022 | 54.78% | RBC Capital | $32 → $14 | Maintains | Sector Perform |
| 11/18/2022 | 32.67% | Oppenheimer | $28 → $12 | Downgrades | Outperform → Perform |
| 11/18/2022 | 43.73% | Credit Suisse | $25 → $13 | Downgrades | Outperform → Neutral |
| 11/18/2022 | 286.95% | Chardan Capital | $43 → $35 | Maintains | Buy |
| 11/17/2022 | -22.61% | SVB Leerink | $14 → $7 | Maintains | Market Perform |
| 11/08/2022 | 10.56% | Morgan Stanley | $15 → $10 | Maintains | Underweight |
| 11/03/2022 | 253.79% | RBC Capital | $40 → $32 | Maintains | Sector Perform |
| 11/03/2022 | 176.4% | Baird | $30 → $25 | Maintains | Outperform |
| 11/03/2022 | 375.4% | Chardan Capital | $60 → $43 | Maintains | Buy |
| 11/03/2022 | 32.67% | SVB Leerink | $14 → $12 | Maintains | Market Perform |
| 09/29/2022 | 99% | B of A Securities | → $18 | Initiates Coverage On | → Neutral |
| 08/04/2022 | 87.95% | Barclays | $16 → $17 | Maintains | Equal-Weight |
| 05/24/2022 | -11.55% | Goldman Sachs | $10 → $8 | Maintains | Sell |
| 05/09/2022 | 65.84% | Morgan Stanley | $17 → $15 | Maintains | Underweight |
| 04/12/2022 | 87.95% | Morgan Stanley | $16 → $17 | Maintains | Underweight |
| 02/25/2022 | 508.07% | Oppenheimer | $80 → $55 | Maintains | Outperform |
| 02/25/2022 | 563.35% | Chardan Capital | $75 → $60 | Maintains | Buy |
| 02/25/2022 | 198.51% | SVB Leerink | $41 → $27 | Maintains | Market Perform |
| 01/06/2022 | 165.34% | Morgan Stanley | $37 → $24 | Maintains | Underweight |
| 10/19/2021 | 353.29% | SVB Leerink | → $41 | Initiates Coverage On | → Market Perform |
| 09/24/2021 | 618.63% | Stifel | → $65 | Initiates Coverage On | → Hold |
| 09/10/2021 | 784.47% | Oppenheimer | $42 → $80 | Upgrades | Perform → Outperform |
| 08/09/2021 | 784.47% | Truist Securities | $45 → $80 | Upgrades | Hold → Buy |
| 08/05/2021 | 563.35% | Evercore ISI Group | $20 → $60 | Upgrades | Underperform → Outperform |
| 05/10/2021 | 309.07% | Morgan Stanley | $40 → $37 | Maintains | Underweight |
| 05/04/2021 | 342.23% | RBC Capital | → $40 | Initiates Coverage On | → Sector Perform |
| 04/16/2021 | 121.12% | Goldman Sachs | → $20 | Initiates Coverage On | → Sell |
| 03/22/2021 | 541.24% | Credit Suisse | → $58 | Initiates Coverage On | → Outperform |
| 03/02/2021 | 342.23% | Morgan Stanley | $45 → $40 | Maintains | Underweight |
| 03/01/2021 | 408.57% | Barclays | → $46 | Downgrades | Overweight → Equal-Weight |
| 02/26/2021 | 397.51% | Truist Securities | → $45 | Downgrades | Buy → Hold |
| 02/10/2021 | 751.3% | Chardan Capital | $55 → $77 | Maintains | Buy |
| 01/19/2021 | 397.51% | Morgan Stanley | $64 → $45 | Downgrades | Equal-Weight → Underweight |
| 01/08/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 12/16/2020 | 607.57% | Morgan Stanley | $30 → $64 | Maintains | Equal-Weight |
| 12/10/2020 | 662.85% | Wells Fargo | $28 → $69 | Upgrades | Equal-Weight → Overweight |
| 11/11/2020 | 231.67% | Morgan Stanley | $31 → $30 | Maintains | Equal-Weight |
| 11/06/2020 | 563.35% | Raymond James | $65 → $60 | Maintains | Outperform |
| 11/03/2020 | 54.78% | Baird | → $14 | Initiates Coverage On | → Underperform |
| 10/13/2020 | 242.73% | Morgan Stanley | $32 → $31 | Maintains | Equal-Weight |
| 08/10/2020 | 253.79% | Morgan Stanley | $27 → $32 | Maintains | Equal-Weight |
| 08/07/2020 | 618.63% | Raymond James | $46 → $65 | Maintains | Outperform |
| 06/18/2020 | 397.51% | SunTrust Robinson Humphrey | → $45 | Initiates Coverage On | → Buy |
| 05/11/2020 | 198.51% | Morgan Stanley | $30 → $27 | Maintains | Equal-Weight |
| 02/27/2020 | 353.29% | Raymond James | $44 → $41 | Maintains | Outperform |
| 02/21/2020 | 209.56% | Wells Fargo | → $28 | Initiates Coverage On | → Equal-Weight |
| 04/12/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 02/08/2019 | 231.67% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 09/21/2018 | 342.23% | Raymond James | → $40 | Initiates Coverage On | → Outperform |
What is the target price for Editas Medicine (EDIT)?
The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on August 29, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 54.78% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Editas Medicine (EDIT)?
The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
Is the Analyst Rating Editas Medicine (EDIT) correct?
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $9.05, which is within the analyst's predicted range.